Danish MD, postdoc at #Mayoclinic, Department of #Cardiology. Collecting my jar of a good living life.
Odense, Danmark
Joined July 2020
- Tweets98
- Following383
- Followers207
- Likes569
Massar retweeted
New in #EJPC: “Effects of empagliflozin in patients at risk of heart failure: the EMPIRE Prevent Metabolic Trial”
🔍 In people with overweight/obesity without diabetes, empagliflozin reduced extracellular volume—a key HF risk mechanism—while epicardial fat remained unchanged.
👉 ow.ly/OBL250Y3BOW
@EJPCEiC @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
The Research Strategy Group met to shape the 2026-2030 strategy for @OUHhospital @kliniskinstitut, where I participated on focusing on global collaboration and research excellence. Grateful for a great team and insightful discussions.
1
3
316
The DanGerShock trial - a significant reduction of mortality with the use of the Impella device in cardiogenic shock patients 🫀! @NEJM @Abiomed @RigsHeart @CHassager JacobEMoller @PCRonline
Do we have a new option in the treatment of #CardShock related to #AMI?
Past ACVC President @CHassager together with Prof. Jacob E Moeller just published the long awaited results of the DanGer Shock trial #ACC24
⬇️ mortality #MCS vs standard care alone
nejm.org/doi/full/10.1056/NE…
2
442
Massar retweeted
This Mayo Clinic study on 476 #HFpEF patients reveals crucial insights:
Only 26% had no atrial #myopathy, while 31% had isolated LA myopathy, 39% biatrial, and 4% isolated right atrial (RA).
Biatrial myopathy linked to worse outcomes: more #AFib , left and right ventricular dysfunction, severe pulmonary disease, and a staggering 84% higher risk of HF 🏥 or death compared to isolated LA myopathy
onlinelibrary.wiley.com/doi/…
@ESC_Journals @EJHFEiC
Massar retweeted
The effect of #SGLT2i on left cardiac remodelling in #HFrEF: Systematic review and meta-analysis
onlinelibrary.wiley.com/doi/…
@ESC_Journals
Massar retweeted
& discussion w/ Drs. Emil Wolsk (@HGHHjerte), Henrik Wiggers (@AUHCardio) & RN Camilla Thomassen (OUH). Multifactorial disease surveillance by #MDT?
#GP, #HF_clinic, #dyspnoea_clinic?
@SLKristensen @FinnGustafsson
#DCS_HF2023 @Pallisgaard_MD @kr_johanna
Massar retweeted
While waiting for #heartfailure data from SELECT a glimpse of potential benefit in PPL with #obesity with HFpEF from STEP HFpEF with 2.4mg semaglutide #heartdisease novonordisk.com/content/dam/…
#SGLT2i's benefit in #HFpEF, but why and how?
First in HFpEF! SGLT2i's effect on #PCWP by #RHC in a mechanistic randomized trial. #Dapa⬇️PCWP, improving the fundamental hemodynamic abnormality underlying HFpEF. @CircAHA @MayoClinic @yreddyhf #Borlaugslab ahajournals.org/doi/10.1161/…
Massar retweeted
What would you do? Low output heart failure (what CCU literature would call cardiogenic shock) with severe pulm HTN and severe MR on echo, EF 20%, max tolerated GDMT, low CO 2.4 L/min (CI 1.6). Despite severe MR mean PCWP only 24, but mean PA 57, PVR 14.
Promising preliminary findings in this experimental study!
Results from the STEP #HFpEF: once-weekly #semaglutide in people with HFpEF and #obesity, will be presented at the #ESC conference 25. August!
"The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF"
jacc.org/doi/epdf/10.1016/j.…
Working up appetite for the results of the STEP-HFpEF trials! clinicaltrials.gov/study/NCT…
clinicaltrials.gov/study/NCT…
8
416
Exploring the phenotypes of #HFpEF may help better identify HFpEF risk profile and may be more amenable specific treatment? We found that 10–25% with HFpEF without #lung disease develop arterial #hypoxemia during #exercise.
@MayoClinic @CardResearchOuh @yreddyhf Borlaug
1/2
2/2
Arterial hypoxemia was found to be related to greater elevation in pulmonary vascular pressures at rest and with exercise, and was associated with increased risk of death in HFpEF.
onlinelibrary.wiley.com/doi/…
Massar retweeted
Next yrs Danish HF meeting will be in Aarhus -and my tenure as organizer has come to an end after 6 yrs, Thx to co-organizers @mortschou, @FinnGustafsson, Lars Køber, Lærke Nelson, @JawadHButt, @ARuwald, @DrEdinaH, @JulieVishram, @MassarOmard, @cardio_dk and pharma for support!
Massar retweeted
Our 💙❤️ beat for the Empire Prevent Trial in both Odense @CardResearchOuh and Copenhagen @HGHHjerte.
So proud to be working with the team: @FuchsAndersen, @mortschou and Jacob Eifer Møller🫀🫀 – at Assens, Danmark
Empire Prevent 🩵🩷 includes patients in Odense @CardResearchOuh and Copenhagen @HGHHjerte. We greatly appreciate our collaboration with @SDCOdense and @RigsHeart 🩵🩷
Well deserved award 🍾🍾
Huge congrats to Prof. Jacob Eifer Møller with the @novonordiskfond Clinical Distinguished Investigator 2023 - and the DKK 10 mio that follows! 🎉
Jacob receives the award for his research with mechanical circulatory support in cardiogenic shock.
@OUHhospital
@RigsHeart
3
187
Teaming up again with #Borlaugslab. This paper highlights the hemodynamic differences in #HFpEF with #LVEF > 65%. We should rethink some aspects in future HFpEF trials.
@AlessioAlogna @yreddyhf @BurkhoffMd @MayoClinicCV @CardResearchOuh @HFA_President
I would say this paper is probably a game changer due to the explanation of the absence of neurohormonal antagonists and by raising new hypothesis for future HFPEF trials. @GianluSava @mewton_nathan @ARakisheva @m_piepoli @cardioceptor @BiykemB @WilfriedMullens @MarcoMetra
Massar retweeted
Patient #100 randomized in Empire Prevent
Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): a randomized controlled trial.
Collaboration between @CardResearchOuh and @HGHHjerte.
Massar retweeted
New results, EMPIRE HF - by PhD student @jhempelheart;
▶️ The effect of empagliflozin (10mg/d/12w) on cardiac structure and function vs placebo - NOT affected by background treatment with angiotensin receptor-neprilysin inhibitor
@RigsHeart @HGHHjerte
sciencedirect.com/science/ar…
Massar retweeted
JULELÆSNING: Få læger får en stilling, der er delt mellem klinik og forskning. 34-årige Lars Wiuff Andersen er en af dem. Forskning i international klasse kan godt lade sig gøre alligevel, for lægerne forsker i deres fritid. Men er det rimeligt? #sundpol
buff.ly/3V6LOFl